Aralez Pharma (ARLZ) Misses Q1 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Aralez Announces First Quarter 2018 Financial Results
May 8, 2018 6:57 AM EDT-1Q 2018 Net Revenues Increased to $38.1 Million Versus $26.0 Million in 1Q 2017-
MISSISSAUGA, Ontario, May 8, 2018 /PRNewswire/ --Â Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ) (TSX: ARZ) ("Aralez" or the "Company")Â today announced financial results for the first quarter ending March 31, 2018. The Company also highlighted certain recent corporate and commercial updates. All figures are in U.S. dollars.
Recent Corporate & Commercial Updates
Earlier today, the Company announced that it has determined that a new strategic direction with a... More